Heron Therapeutics Inc (NASDAQ:HRTX) Receives $58.00 Consensus Target Price from Analysts

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have been assigned a consensus recommendation of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $58.00.

Several equities analysts recently issued reports on the company. Northland Securities reiterated a “buy” rating and issued a $55.00 price objective on shares of Heron Therapeutics in a research report on Monday, August 5th. Cowen reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, May 9th. Stifel Nicolaus reiterated a “buy” rating and issued a $38.00 price objective on shares of Heron Therapeutics in a research report on Monday, August 5th. Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 9th. Finally, BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virginia Retirement Systems ET AL lifted its stake in Heron Therapeutics by 2.3% in the 1st quarter. Virginia Retirement Systems ET AL now owns 36,100 shares of the biotechnology company’s stock valued at $882,000 after acquiring an additional 800 shares in the last quarter. Chartwell Investment Partners LLC lifted its stake in Heron Therapeutics by 1.1% in the 2nd quarter. Chartwell Investment Partners LLC now owns 100,171 shares of the biotechnology company’s stock valued at $1,862,000 after acquiring an additional 1,129 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Heron Therapeutics by 247.4% during the 1st quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 1,200 shares in the last quarter. Meadow Creek Investment Management LLC bought a new stake in shares of Heron Therapeutics during the 2nd quarter worth approximately $27,000. Finally, Legal & General Group Plc raised its stake in shares of Heron Therapeutics by 6.5% during the 4th quarter. Legal & General Group Plc now owns 27,564 shares of the biotechnology company’s stock worth $716,000 after purchasing an additional 1,679 shares in the last quarter.

Shares of HRTX traded down $0.03 on Friday, hitting $17.97. The company’s stock had a trading volume of 3,670 shares, compared to its average volume of 877,333. The company has a quick ratio of 3.70, a current ratio of 4.01 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average price is $17.88 and its 200-day moving average price is $21.29. Heron Therapeutics has a fifty-two week low of $15.68 and a fifty-two week high of $41.10. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -7.33 and a beta of 1.49.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. Heron Therapeutics had a negative return on equity of 56.89% and a negative net margin of 172.07%. The business had revenue of $36.66 million during the quarter, compared to analyst estimates of $31.04 million. As a group, equities analysts predict that Heron Therapeutics will post -2.73 earnings per share for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: What is the Ex-Dividend Date in Investing?

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.